0001323885-25-000095
SEC filingStrong 17.1% revenue growth driven by appendage and pain management, partially offset by hybrid procedure decline.
In the second quarter of 2025, AtriCure reported revenue of $136.1 million, a 17.1% increase year-over-year (16.5% on a constant currency basis). Gross margin edged down slightly to 74.5% from 74.7%, attributed to less favorable geographic and product mix. Operating loss improved to $6.2 million from $7.2 million, driven by higher gross profit and controlled SG&A growth (up only 6.5%) despite a surge in R&D expenses. Net loss narrowed to $6.2 million from $8.0 million. For the six months, revenue grew 15.4% to $259.8 million, with gross margin flat at 74.7%. Operating loss improved to $12.1 million from $18.1 million, reflecting strong operating leverage.
Product line performance showed divergent trends. Appendage management revenue rose 18.9% to $45.1 million in Q2, fueled by the AtriClip FLEX-Mini launch. Pain management grew 41.1% to $21.2 million, driven by the cryoSPHERE MAX probe. Open ablation increased 18.6% to $36.5 million, benefiting from the EnCompass clamp. However, minimally invasive ablation dropped 33.7% to $7.8 million as physicians performed fewer hybrid procedures. US revenue rose 15.7% to $110.6 million, while international grew 23.3% to $25.6 million, with broad gains across regions.
Management highlighted product innovation and clinical trials as strategic priorities. The recently cleared AtriClip PRO-Mini and cryoXT probe are expected to launch in H2 2025. The LeAAPS trial completed enrollment of 6,500 patients, supporting future label expansion. The BoxX-NoAF trial is anticipated to begin enrollment later this year. No quantitative guidance was provided, but continued investment in R&D and training is expected to sustain growth, albeit with potential headwinds from new competitors and macroeconomic factors.
As of June 30, 2025, AtriCure holds $117.8M in cash and cash equivalents, a slight decrease from $122.7M at year-end 2024. Total assets are $608.8M, with $52.2M in intangible assets and $234.8M in goodwill. Working capital (current assets minus current liabilities) stands at $202.4M ($271.3M - $68.8M). The company has $61.9M in long-term debt under its ABL facility, unchanged from December 31, 2024, with a maturity date of January 5, 2027. The effective interest rate is 7.16%. Stockholders' equity increased to $464.5M from $461.0M, driven by share-based compensation and comprehensive income.
AtriCure has no significant material purchase commitments disclosed. The Cooperation Agreement with a pulsed field ablation technology partner includes contingent consideration up to $28M, with $5M paid in the first half of 2025 (expensed as R&D). A clinical trial management agreement for the LeAAPS trial requires milestone payments over ten years, with $7.5M paid in six months. A legal contingency exists from a SentreHEART acquisition dispute seeking up to $260M in damages; management believes the claim is without merit and no liability has been accrued.
No share buybacks or dividends were executed. The company invested $4.8M in property and equipment (capex) during the first half of 2025, representing 1.86% of revenue. Debt levels remained constant with no new borrowings or repayments on the ABL facility. Share-based compensation totaled $21.0M, partially offset by $10.6M in shares repurchased for tax withholding on stock awards.
AtriCure operates as a single segment, but provides revenue by product type and geography. For the six months ended June 30, 2025, total revenue was $259.8M (+15.4% YoY). US revenue was $211.7M (81.5% of total), with International at $48.0M. Product mix: Open ablation $89.1M (34.3%), Minimally invasive ablation $20.7M (8.0%), Pain management $42.3M (16.3%), Appendage management $107.7M (41.4%). Pain management showed the strongest growth at 38.6% YoY, while minimally invasive ablation declined 14.2%.
Operating cash flow (CFO) of $10.6M represents a significant turnaround from a -$13.6M outflow in the prior year period, driven by a reduced net loss and non-cash adjustments (share-based compensation $21.0M, depreciation & amortization $10.3M). Working capital changes were a net use of cash ($13.3M), mainly due to increased accounts receivable and accrued liabilities. Capex of $4.8M was slightly lower YoY, reflecting disciplined spending. Free cash flow (CFO less capex) was $5.7M, compared to -$18.8M in the prior period. Investing activities also included $5.0M for in-process R&D acquisition. Financing activities used $6.9M, with $10.6M in share repurchases for tax withholding partially offset by $4.3M in stock option proceeds. The company ended with $117.8M in cash, down from $122.7M, but remains well-capitalized.